Investor · 1 deal
Every published round BioCurate took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
| Company | Stage | Announced | Amount | Role | Alongside | Sources |
|---|---|---|---|---|---|---|
| xCystence Bio | Pre-seed | 30 Mar 2026 | - | Participant | Uniseed, Breakthrough Victoria |
Companies BioCurate has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| xCystence Bio | 30 Mar 2026, Pre-seed | 1 | 0 |
Fund closes reported for BioCurate, as distinct from the investments it has made.
Companies BioCurate has backed that another company then bought. An exit for the holding, not a deal BioCurate did.
Stories naming BioCurate. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
xCystence Bio secured pre-seed funding from Uniseed, Monash Ventures, Breakthrough Victoria, and BioCurate to develop targeted protein degraders for treating genetic kidney disease.
Breakthrough Victoria reports investing in xCystence Bio, a Monash University spinout developing polycystic kidney disease therapies, via its University Innovation Platform alongside BioCurate and UniSeed.
Also Uniseed
Uniseed chief executive Peter Devine departs after two decades; Monash's Alistair Hick takes over in 2026. The piece recounts Uniseed's fund history and recent stakes in ENA Respiratory and Morse Micro rounds.
Cincera Therapeutics has received a million-dollar Biomedical Translation Bridge grant to advance its Des-1 inhibitor drug for obesity-related metabolic diseases. The Monash and UniSA spin-out previously secured venture funding from the Medical Research Commercialisation Fund.